Saturday, October 31, 2026

Starbucks Stock Is 5% Up So Far Today

ViaNews Editorial Team

December 10, 2020

Starbucks Stock Is 5% Up So Far Today
Shares of Starbucks rose 5.29% to $105.71 at 14:07 EST on Thursday, after three sequential sessions in a row of losses. The Nasdaq Stock Market is jumping 0.52% to $12,403.50, following yesterday's downward trend, on what at the moment seems, a somewhat positive trend exchanging session today. Starbucks's last close was $100.40, 0.04% under its 52-week high of $105.75.

News about Starbucks today

Mellody hobson, new chair of the Starbucks board, is a big champion of financial literacy. According to today's article on CNBC, "Mellody Hobson, named Starbucks' new board chair on Wednesday, knows what it is like to grow up without money." Some like it cold: Starbucks sold $1 billion in chilled drinks in last 3 years. According to today's article on MarketWatch, "Starbucks Corp. is building on its line of cold beverages, which the global coffee company says has already driven $1 billion in sales over the last three years."

Starbucks's Sales

Starbucks's sales growth is a negative 1.9% for the present quarter and 11.5% for the next. The company's growth estimates for the ongoing quarter is a negative 29.1% and positive 84.4% for the next.

Starbucks's Revenue

Year-on-year quarterly revenue growth declined by 8.1%, now sitting on 23.52B for the twelve trailing months.

Starbucks's Stock Top and Bottom Yearly Value

Starbucks's stock is valued at $105.71 at 14:07 EST, below its 52-week high of $105.75 and way higher than its 52-week low of $50.02.

Starbucks's Moving Average

Starbucks's value is way above its 50-day moving average of $94.63 and way higher than its 200-day moving average of $83.90.

Previous days news about Starbucks

Starbucks names mellody hobson chair in gain for black directors. According to Bloomberg Quint on Wed Dec 9, "Starbucks Corp. named finance executive Mellody Hobson to lead its board as chair, making her one of the highest-profile Black directors in corporate America." Starbucks names mellody hobson board chairwOman. According to The Wall Street Journal on Wed Dec 9, "Starbucks Corp. said investor Mellody Hobson has been appointed nonexecutive chairwoman of the company’s board." Starbucks boosts outlook, sees 20,000 more cafes with worst over. According to Bloomberg Quint on Wed Dec 9, "The notion of a Starbucks Corp. on every corner is back, with the chain planning to build more than 20,000 additional locations in the next decade after it has left the pandemic in its wake." Starbucks stock rises after retailer's guidance calls for 'significant' 2021 rebound. According to MarketWatch on Wed Dec 9, "Shares of Starbucks Corp. rose more than 4% in the extended session Wednesday after the retailer reiterated its guidance for next year and said that it is counting on a "significant rebound" for 2021."

In this story · Knowledge Files

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com